首页> 外文期刊>Clinical and experimental hypertension: CEH >Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study
【24h】

Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study

机译:初始血管紧张素受体阻滞剂对单纯性高血压患者治疗持久性的影响:一项基于全国人群的研究

获取原文
获取原文并翻译 | 示例
           

摘要

We identified 55 504 uncomplicated, treatment-naive hypertensive patients who started angiotensin II receptor blockers (ARBs) in 2012 from national claims data. The proportion of patients remaining on any hypertension treatment at 12 months and the adherence rate were similar between the losartan cohort (66.82% and 68.25%) and the nonlosartan ARB cohort (67.48% and 69.01%). After adjusting for confounding factors, there was no difference in persistence (aHR 0.98, 95% confidence interval (CI) 0.95-1.01) on hypertension treatment between losartan and nonlosartan ARB cohort. Post hoc analysis showed that patients initially prescribed eprosartan, irbesartan (both, aHR 1.33), and telmisartan (aHR 1.11) were more likely to discontinue the initial drug, whereas valsartan initiators (aHR 0.96) were less likely compared with losartan initiators.
机译:我们从国家索赔数据中发现了55504名无并发症,未经治疗的高血压患者,他们于2012年开始使用血管紧张素II受体阻滞剂(ARB)。氯沙坦组(66.82%和68.25%)和非氯沙坦ARB组(67.48%和69.01%)在12个月时仍接受任何高血压治疗的患者比例和依从率相似。调整混杂因素后,氯沙坦和非氯沙坦ARB组的高血压治疗持续性(aHR 0.98,95%置信区间(CI)0.95-1.01)没有差异。事后分析表明,最初开具依普沙坦,厄贝沙坦(均为aHR 1.33)和替米沙坦(aHR为1.11)的患者较最初停药的可能性更高,而缬沙坦引发剂(aHR 0.96)与氯沙坦引发剂的可能性较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号